Nucleo CMP Forte

Phase 3Small molecule

SSherief Abd-Elsalam

Nucleo CMP Forte is one of 54 small molecule programs targeting Brain Injury. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Brain InjuryRecruiting

Brain InjuryPhase 3

Recruiting

Competition

Competitive Landscape

62 competitors in Brain Injury

#DrugCompanyPhaseTrials

Ritalin

Novartis

Approved

4 2

Keppra

UCB

Approved

4 3

Namenda

AbbVie

Approved

3 4

Buspar

Bristol-Myers Squibb

Approved

2 5

Celexa

AbbVie

Approved

2 6

Vimpat

UCB

Approved

2 7

Rozerem

Takeda

Approved

1 8

Exelon

Novartis

Approved

1 9

Vyvanse

Takeda

Approved

1 10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 3Recruiting

Brain Injury

NCT04499755

Clinical

Trials by Indication[1]

Brain Injury1 trial

Efficacy of Nucleo CMP Forte in Traumatic Brain Injury in Pediatrics

Recruiting·SSherief Abd-Elsalam·Phase 3·NCT04499755·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nucleo CMP Forte. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nucleo CMP Forte compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nucleo CMP Forte. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sherief Abd-Elsalam company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSherief Abd-Elsalam

Nucleo CMP Forte

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Brain Injury1 trial

References

Drug Info

Quick Facts

Related News